The California Drug Price Relief Act, also known as Proposition 61- THE STATE PRESCRIPTION DRUG PURCHASES.

PRICING STANDARDS.

INITIATIVE STATUTE, is a state ballot measure that will be voted on in the California, November 2016, statewide elections.

The California Drug Price Relief Act proposes that the state of California pay no more to pharmaceutical companies, for Medicare and Medicaid drugs, than the United States Department of Veteran Affaris pays for its drugs.

The AIDS Healthcare Foundation is sponsoring the bill, to the tune of $4,377,075 million (US).

Fifteen pharmaceutical companies have joined forces to lobby against the bill, and as of June 2016, had collectively doled out $58,800,000 to make sure the bill does not become law.

This is the largest opposition lobby for a state measure, that will be on the November 2016 ballot.

The Following Pharmaceutical Companies have raised a total of $58.8 million, to lobby against the bill:

Merck & Co., Inc.- $5,860,000

Pfizer Inc.- $5,860,000

Johnson & Johnson- $5,860,000

Sanofi-Aventis U.S. LLC- $4,265,000

AstraZeneca Pharmaceuticals LP- $4,265,000

Amgen Inc.- $4,265,000

Abbvie Inc.- $4,265,000

Gilead Sciences, Inc.- $4,000,000

Biogen, Inc.- $2,880,000

GlaxoSmithKline- $2,880,000

Allergan- $2,880,000

Novo Nordisk- $2,880,000

Novartis Pharmaceuticals Corporation- $2,880,000

Eli Lily & Co.- $2,880,000

Bristol-Myers Squibb Co.- $2,880,000